Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
  • Protocols
  • AAV Purification by Iodixanol Gradient Ultracentrifugation

AAV Purification by Iodixanol Gradient Ultracentrifugation

You may also like...

Introduction

This protocol can be used to purify AAV of any serotype.

In medicine, iodixanol can be used as an intravenous isomolar contrast agent. In research, iodixanol is used as an isomolar density gradient medium suitable for virus purification and isolation of cells, organelles, lipoproteins, and macromolecules. Importantly, iodixanol is inert and non-toxic to mammalian cells. Therefore, and unlike other density gradient media, it is reportedly not necessary to remove iodixanol prior to use of your purified virus. Nonetheless, we recommend performing a buffer exchange before using the purified AAV in vivo .

The iodixanol gradient in this protocol is composed of steps that separate out contaminants from an impure AAV preparation. The 15% iodixanol step has 1M NaCl to destabilize ionic interactions between macromolecules. The 40% and 25% steps are used to remove contaminants with lower densities, including empty capsids. The 60% step serves as a cushion for genome-containing virions. Phenol red is added to clearly distinguish the steps. This method will help enrich the prep with full (genome containing) particles. On average, iodixanol-purified AAV preparations contain ~20% empty particles.

60% iodixanol solution is available under the name OptiPrep from Sigma-Aldrich.

Last Upload: January 17, 2018

Protocol Video Icon
Protocol Video

Watch the protocol video below to learn setup and use an iodixanol column gradient for AAV purification.

Workflow Timeline

Day 1: Purify

Day 2: Buffer exchange and concentration

Note: Both steps could be completed in one (long) day.

Equipment

  • Ultracentrifuge
  • T70i rotor or equivalent

Reagents

  • Opti-Prep (60% Iodixanol)
  • QuickSeal tubes
  • QuickSeal tube spacers
  • 16 ga needle
  • 18 ga needle
  • 10 mL syringe
  • 1x PBS pH 7.4
  • 1x PBS-MK buffer
  • 100X Pluronic-F68
  • NaCl
  • MgCl2
  • KCl
  • Centrifugal filter units (MWCO 100 kDa)

Reagent Preparation

  1. 1 M NaCl/PBS-MK buffer

    • Dissolve 5.84 g of NaCl, 26.3 mg of MgCl2and 14.91 mg of KCl in 1× PBS in a final volume of 100 mL. Sterilize by passing through a 0.22-μm filter and store at 4 ℃.

  2. 1x PBS-MK buffer
    • Dissolve 26.3 mg of MgCl2, and 14.91 mg of KCl in 1× PBS in a final volume of 100 mL. Sterilize by passing through a 0.22-μm filter and store at 4 ℃.
  3. 0.001% Pluronic-F68 (formulation buffer)
    • Add 5 μL of 100X Pluronic F-68 to 49.95 mL of PBS. Store at 4 ℃ for up to one month, or aliquot and store at -80 ℃ for up to one year.

Procedure

  1. Preparation and loading of the iodixanol gradient:
    • 15% iodixanol step: mix 4.5 mL of 60% iodixanol and 13.5 mL of 1 M NaCl/PBS-MK buffer
    • 25% iodixanol step: mix 5 mL of 60% iodixanol and 7 mL of 1x PBS-MK buffer and 30 μL of phenol red
    • 40% iodixanol step: mix 6.7 mL of 60% iodixanol and 3.3 mL of 1x PBS-MK buffer
    • 60% iodixanol step: mix 10 mL of 60% iodixanol and 45 μL of phenol red
  2. Overlay each solution into a QuickSeal tube in the order below using a 10 mL syringe and an 18 g needle, taking care to avoid bubbles (Figure 1).
    1. 5 mL of 60% iodixanol step
    2. 5 mL of 40% iodixanol step
    3. 6 mL of 25% iodixanol step
    4. 8 mL of 15% iodixanol step
  3. Carefully add up to 5 mL of clarified supernatant on top of the gradient. Use 1x PBS (or cell lysis buffer) to top off the tube.
  4. Seal the QuickSeal tubes.
  5. Centrifuge at 350,000 g for 90 min in a T70i rotor at 10 ℃.
    *Pro-Tip* If you need more time, you can alternatively centrifuge for 2 h at 200,000 g at 18 ℃.
  6. Carefully take the QuickSeal tubes out of the rotor and place them in a stable rack. **Make sure not to disturb the gradient!**
  7. Collect Fractions

    Option #1

    • Prepare a row of roughly 20 open 1.5 mL microcentrifuge tubes in a rack. These will be used to collect fractions from the gradient. You can collect fewer fractions once you have a good idea when the virus elutes from the gradients.
    • In a biosafety cabinet, carefully puncture the QuickSeal tube at the interface of the 60% and 40% gradient (see Figure 2) with an 18 g needle.
    • Place the first microcentrifuge tube under the needle’s opening to collect the fractions.
    • Puncture the top of the QuickSeal tube with a 16 ga needle and start collecting 0.5 mL to 1 mL fractions per tube.
    • Avoid the proteinaceous material near the 40-25% interface.
    *Pro-Tip* As soon as the top of the tube is punctured, AAV-containing Iodixanol solution will flow from the needle set at the 40-60% interface. Make sure that the microcentrifuge tubes are well positioned to collect the solution or you will lose a significant amount of your virus. When the first fraction is collected, move the rack to the next empty tube to collect the next fraction. The flow will be rapid at first and will progressively slow down.

    Option #2

    • Puncture the QuickSeal tube at the bottom using an 18 g needle.
    • Immediately start collecting 0.5 to 1 mL fractions in microcentrifuge tubes.
    • Repeat for each QuickSeal tube.
    • The first 8 mL collected corresponds to the 60% phase and can be discarded.
    • The fractions obtained from the 40% phase contain the purified AAV.

    Option #3

    • Puncture the QuickSeal tube slightly below the 60-40% interface with an 18 g needle attached to a 10 mL syringe.
    • The bevel of the needle should be up, facing the 40% step.
    • Collect up to 5 mL per tube, taking care to avoid collecting the proteinaceous material at the 40-25% interface.
    • Repeat for each QuickSeal tube.
  8. (Optional) For first time users, it is a good idea to assay each fraction by silver stain to determine purity. Only the cleanest fractions should be kept and pooled for dialysis.
  9. Pool clean fractions.
  10. Concentration and buffer exchange:

    Stocks of Pluronic F68:

    • Pluronic F68, 10% solution
    • A: 0.1% in PBS: 49.5 ml PBS + 500 µl Pluronic F68
    • B: 0.01% in PBS: 45 ml PBS + 5 ml A
    • C: 0.001% in PBS: 45 ml PBS + 5 ml B + 200 mM NaCl

    Procedure:

    1. Cover the filter membrane with 15 ml of 0.1% Pluronic F68 PBS and incubate for 10 min at room temperature
    2. Take out the 0.1% Pluronic F68 PBS and add 15 ml of 0.01% Pluronic F68 PBS.
    3. Spin at 3000 RPM for 5 min at 4 ℃
    4. Discard the flow through and add 15 ml of 0.001% Pluronic F68 + 200mM NaCl PBS.
    5. Spin at RPM rpm for 5 min at 4 ℃.
    6. Discard the flow through and add your sample.
    7. Spin at 3500 RPM for 8 min at 4 ℃, discard the flow through.
    8. Add more sample and spin 3500 rpm for 4 min at 4°C, discard the flow through. Repeat this step as needed.
      • Please note that iodixanol is not easily removed. After each spin, add more formulation buffer and sample and make sure to pipet back and forth a few times to mix the iodixanol that has settled at the bottom of the column.
      • We recommend concentrating to a minimum of 500 µl. If the concentrate volume is less than 500 µl, bring up the volume with formulation buffer.
    9. Use a P1000 to the bottom of the filter and pipette up/down and wash off the walls of the filter to recover as much virus as possible.
  11. Store at 4 ℃ for short term (2 weeks), or aliquot and store at -80 ℃ for long term.

Sample Data

A profile view of an iodixanol density gradient before ultracentrifugation appears as discrete layers thanks to the use of phenol red as a dye.

Figure 1: Iodixanol gradient before ultracentrifugation. The steps are clearly distinguishable thanks to the use of phenol red. Image adapted from Zolotukhin, S., et al. "Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield." Gene therapy 6.6 (1999): 973-985.

The left panel is a profile photo of an iodixanol gradient after ultracentrifugation. The interfaces between layers are muddled due to the passage of supernatant through each layer. The right panel illustrates a gradient tube before and after ultracentrifugation. The viral supernatant migrates through increasingly dense layers until the macromolecule density is equal to the buoyant force of the solution. Contaminants of lower densities are captured at the 17%, 25%, and 60% layers, and genome-containing virions are captured at the 40% layer. To collect purified AAV, insert a syringe at the interface of the 40% layer containing the virus and 60% iodixanol layer, with the bevel pointed up. A syringe at the top of the tube allows air to enter the column so the virus will flow out the bottom syringe.

Figure 2: Left panel: Iodixanol gradient after ultracentrifugation. The arrow indicates the 60-40% interface. The vertical black line indicates the location of the purified AAV. Left image adapted from Zolotukhin, S., et al. "Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield." Gene therapy 6.6 (1999): 973-985 .

Right panel: cartoon indicating the position of the needle for harvesting of the purified AAV using option #1. Right image adapted by permission from Macmillan Publishers Ltd: Nature Protocols Grieger, Joshua C., Vivian W. Choi, and R. Jude Samulski. "Production and characterization of adeno-associated viral vectors," copyright (2006).

Silver-stained protein gel of 10 consecutive AAV purification fractions separated by SDS-PAGE. Lanes of fractions 3 to 12 are flanked by a protein ladder (M), which indicates the molecular weights in kDa. Asterisks mark the AAV capsid proteins (VP1, VP2, VP3) at positions 87, 73, and 62 kDa, respectively. An increased number of contaminants in each fraction is observed as a smear of protein bands in each lane.

Figure 3: Example of an SDS-PAGE gel of 10 consecutive gradient fractions followed by silver stain. Note the increased number of contaminants in each fraction. * AAV capsid proteins VP1, VP2, VP3; M protein marker. Image adapted from Strobel Benjamin, Miller Felix D., Rist Wolfgang, and Lamla Thorsten. Human Gene Therapy Methods. August 2015, 26(4): 147-157. doi:10.1089/hgtb.2015.051.